Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

RAPID MIGRAINE RELIEF WITH ALGINATE-BASED THIN FILM

Ziel

Klaria's business concept is based on developing and commercializing innovative, fast-acting medicinal products with clear competitive benefits in the therapeutic fields of migraine and cancer-related pain. Migraine is the sixth most disabling illness in the world. The economic burden of migraine predominantly falls on patients and their employers in the form of bedridden days and lost productivity. The illness is three times as common in women than in men. However, existing drug delivery methods are not effective which results in low therapy satisfaction rates amongst migraine patients.

Klaria developed an alginate-based polymer film capable of rapidly delivering the API (active pharmaceutical ingredient) directly into the bloodstream. The thin film is similar to a small postage stamp and is discreetly attached to the oral mucous membrane and allows the medication to be distributed into the bloodstream through the oral mucous membrane. The substance is delivered much more quickly (and thereby has a faster impact) than substances which are swallowed in tablets or capsules. Klaria’s film does not require taking an injection or suppository and ensures early intervention which is critical in order for migraine patients to experience pain relief. The film can be used by all migraine patients using medications based on triptans including those who experience concomitant vomiting during their migraine attack.

Project RAPID, aims therefore to exploit the positive clinical performance of the buccal adhesive film, the company’s IP position and its ability to manufacture cost-effectively to launch an innovative migraine to contribute to an improved quality of life for migraine patients.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

SME-2 - SME instrument phase 2

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) H2020-EIC-SMEInst-2018-2020

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

KLARIA AB
Netto-EU-Beitrag
€ 2 031 574,13
Adresse
VIRDINGS ALLE 2
754 50 UPPSALA
Schweden
KMU
Ja
Region
Östra Sverige Östra Mellansverige Uppsala län
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 2 902 248,75